|
1
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saeki H, Hlaing MT, Horimoto Y, Kajino K,
Ohtsuji N, Fujino K, Terao Y and Hino O: Usefulness of
immunohistochemistry for mismatch repair protein and microsatellite
instability examination in adenocarcinoma and background
endometrium of sporadic endometrial cancer cases. J Obstet Gynaecol
Res. 45:2037–2042. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeSantis CE, Ma J, Gaudet MM, Newman LA,
Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer
statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Davies C, Godwin J, Gray R, Clarke
M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance
of breast cancer hormone receptors and other factors to the
efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fisher B, Costantino JP, Redmond CK,
Fisher ER, Wickerham DL and Cronin WM: Endometrial cancer in
tamoxifen-treated breast cancer patients: Findings from the
national surgical adjuvant breast and bowel project (NSABP) B-14. J
Natl Cancer Inst. 86:527–537. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Braithwaite RS, Chlebowski RT, Lau J,
George S, Hess R and Col NF: Meta-analysis of vascular and
neoplastic events associated with tamoxifen. J Gen Intern Med.
18:937–947. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shang Y and Brown M: Molecular
determinants for the tissue specificity of SERMs. Science.
295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jordan VC and Assikis VJ: Endometrial
carcinoma and tamoxifen: Clearing up a controversy. Clin Cancer
Res. 1:467–472. 1995.PubMed/NCBI
|
|
9
|
Davies C, Pan H, Godwin J, Gray R,
Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A,
Bonfill X, et al: Long-term effects of continuing adjuvant
tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive breast cancer: ATLAS, a randomised
trial. Lancet. 381:805–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Droog M, Nevedomskaya E, Kim Y, Severson
T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus
G, et al: Comparative cistromics reveals genomic cross-talk between
FOXA1 and ERα in tamoxifen-associated endometrial carcinomas.
Cancer Res. 76:3773–3784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Turbiner J, Moreno-Bueno G, Dahiya S,
Sánchez-Estevez C, Hardisson D, Prat J, Oliva E and Palacios J:
Clinicopathological and molecular analysis of endometrial carcinoma
associated with tamoxifen. Mod Pathol. 21:925–936. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki O, Eguchi H, Chika N, Sakimoto T,
Ishibashi K, Kumamoto K, Tamaru JI, Tachikawa T, Akagi K, Arai T,
et al: Prevalence and clinicopathologic/molecular characteristics
of mismatch repair-deficient colorectal cancer in the
under-50-year-old Japanese population. Surg Today. 47:1135–1146.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sasa K, Saito T, Kurihara T, Hasegawa N,
Sano K, Kubota D, Akaike K, Okubo T, Hayashi T, Takagi T, et al:
Establishment of rapid and accurate screening system for molecular
target therapy of osteosarcoma. Technol Cancer Res Treat.
21:153303382211382172022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horimoto Y, Thinzar Hlaing M, Saeki H,
Kitano S, Nakai K, Sasaki R, Kurisaki-Arakawa A, Arakawa A, Otsuji
N, Matsuoka S, et al: Microsatellite instability and mismatch
repair protein expressions in lymphocyte-predominant breast cancer.
Cancer Sci. 111:2647–2654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki Y, Fukumura Y, Asahina M, Fujimaki
M, Ohba S, Matsumoto F, Kurahayashi I, Yao T and Ikeda K: EGFR
protein expression relates with tumor histology, methylation status
of EGFR and HPV16 E6 viral load in oropharyngeal carcinoma. Head
Neck Pathol. 15:743–756. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
House MG, Guo M, Iacobuzio-Donahue C and
Herman JG: Molecular progression of promoter methylation in
intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
Carcinogenesis. 24:193–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prasad M, Wang H, Douglas W, Barakat RR
and Ellenson LH: Molecular genetic characterization of
tamoxifen-associated endometrial cancer. Gynecol Oncol. 96:25–31.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnatty SE, Stewart CJR, Smith D,
Buchanan D, Leung Y, Oehler MK, Brand A, Webb PM and Spurdle AB:
Risk and prognostic factors for endometrial carcinoma after
diagnosis of breast or Lynch-associated cancers-A population-based
analysis. Cancer Med. 7:6411–6422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fisher B, Costantino JP, Wickerham DL,
Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins
JN, Margolese RG, et al: Tamoxifen for the prevention of breast
cancer: Current status of the national surgical adjuvant breast and
bowel project P-1 study. J Natl Cancer Inst. 97:1652–1662. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Latham A, Srinivasan P, Kemel Y, Shia J,
Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A,
Dubard-Gault M, et al: Microsatellite instability is associated
with the presence of Lynch syndrome pan-cancer. J Clin Oncol.
37:286–295. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanaya N, Tanakaya K, Yamasaki R, Arata T,
Shigeyasu K, Aoki H, Morito T, Sanaii H, Akagi K and Fujiwara T:
Clinicopathological features of breast cancer in Japanese female
patients with Lynch syndrome. Breast Cancer. 26:359–364. 2019.
View Article : Google Scholar : PubMed/NCBI
|
